PE20081194A1 - Produccion de glicoproteinas - Google Patents

Produccion de glicoproteinas

Info

Publication number
PE20081194A1
PE20081194A1 PE2007000892A PE2007000892A PE20081194A1 PE 20081194 A1 PE20081194 A1 PE 20081194A1 PE 2007000892 A PE2007000892 A PE 2007000892A PE 2007000892 A PE2007000892 A PE 2007000892A PE 20081194 A1 PE20081194 A1 PE 20081194A1
Authority
PE
Peru
Prior art keywords
glycoprotein
crop
concentration
temperature range
allow
Prior art date
Application number
PE2007000892A
Other languages
English (en)
Inventor
Daniel Lasko
Steve Koza
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38645762&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081194(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20081194A1 publication Critical patent/PE20081194A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN METODO PARA PRODUCIR UNA GLICOPROTEINA TAL COMO EL FACTOR DE COAGULACION HUMANO RECOMBINANTE IX O UN ANTICUERPO MONOCLONAL IgG1 PEPTIDICO ANTI-ABETA HUMANIZADO EN UN CULTIVO CELULAR QUE COMPRENDE: A) CULTIVAR CELULAS DE MAMIFEROS QUE CONTIENEN UN GEN QUE CODIFICA UNA GLICOPROTEINA DE INTERES EN UN MEDIO DE CULTIVO CELULAR QUE COMPRENDE MANGANESO EN UNA CONCENTRACION DE 10nM A 600nM; B) MANTENER EL CULTIVO EN UN PRIMER RANGO DE TEMPERATURA DE 37 ºC DURANTE UN TIEMPO SUFICIENTE PARA PERMITIR A LAS CELULAS REPRODUCIRCE HASTA UNA DENSIDAD CELULAR VIABLE DE 20% A 80%; C) CAMBIAR EL CULTIVO A UN SEGUNDO RANGO DE TEMPERATURA DE 31 ºC DURANTE UN TIEMPO SUFICIENTE PARA PERMITIR LA EXPRESION DE LA GLICOPROTEINA, EN DONDE EL PATRON DE GLICOSILACION DE LA GLICOPROTEINA EXPRESADA ES MAS EXTENSO QUE EL PATRON DE GLICOSILACION OBSERVADO EN CARENCIA DE MANGANESO. DICHO MEDIO DE CULTIVO COMPRENDE ADEMAS GLUTAMINA EN UNA CONCENTRACION DE 8mM Y COMPONENTES SUPLEMENTARIOS TAL COMO HORMONAS, IONES INORGANICOS, VITAMINAS, GLUCOSA, ENTRE OTROS
PE2007000892A 2006-07-13 2007-07-11 Produccion de glicoproteinas PE20081194A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83065806P 2006-07-13 2006-07-13

Publications (1)

Publication Number Publication Date
PE20081194A1 true PE20081194A1 (es) 2008-09-22

Family

ID=38645762

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000892A PE20081194A1 (es) 2006-07-13 2007-07-11 Produccion de glicoproteinas

Country Status (23)

Country Link
US (1) US8129145B2 (es)
EP (3) EP3255141B1 (es)
JP (1) JP5401310B2 (es)
KR (1) KR101495549B1 (es)
CN (2) CN104878064A (es)
AR (1) AR061976A1 (es)
AU (1) AU2007272957B2 (es)
BR (1) BRPI0714212B8 (es)
CA (1) CA2657248C (es)
DK (3) DK3255141T3 (es)
ES (2) ES2440487T3 (es)
HK (1) HK1214307A1 (es)
HU (1) HUE039128T2 (es)
IL (1) IL196252A (es)
MX (1) MX2009000349A (es)
PE (1) PE20081194A1 (es)
PL (2) PL2495307T3 (es)
PT (2) PT2041270E (es)
RU (1) RU2463345C2 (es)
SI (1) SI2495307T1 (es)
TR (1) TR201807021T4 (es)
TW (1) TW200812577A (es)
WO (1) WO2008008360A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
EP3255141B1 (en) 2006-07-13 2021-12-01 Wyeth LLC Production of antibodies with improved glycosylation pattern
MY161866A (en) 2006-09-13 2017-05-15 Abbvie Inc Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US8192951B2 (en) * 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
DK2115126T3 (en) * 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090233334A1 (en) * 2008-03-11 2009-09-17 Excellgene Sa Cell cultivation and production of recombinant proteins by means of an orbital shake bioreactor system with disposable bags at the 1,500 liter scale
SG10201702922VA (en) 2008-10-20 2017-06-29 Abbvie Inc Isolation and purification of antibodies using protein a affinity chromatography
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
WO2011011674A2 (en) * 2009-07-24 2011-01-27 Dr. Reddy's Laboratories Ltd. Production of erythropoiesis stimulating protein using metal ions
WO2011017177A1 (en) * 2009-07-28 2011-02-10 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
PT2563906T (pt) 2010-04-26 2018-02-16 Novartis Ag Processo para cultivo de células cho
MY163081A (en) * 2010-12-28 2017-08-15 Chugai Pharmaceutical Co Ltd Animal cell culturing method
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
ES2560470T3 (es) 2011-04-29 2016-02-19 Biocon Research Limited Un método para reducir la heterogeneidad de anticuerpos y un proceso de producción de dichos anticuerpos
BR112014001120A2 (pt) 2011-07-20 2017-02-21 Zepteon Incorporated métodos de separação de polipeptídeos
WO2013114245A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014170866A2 (en) * 2013-04-18 2014-10-23 Dr. Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased galactosylation content
JP2016527911A (ja) * 2013-08-20 2016-09-15 レック・ファーマシューティカルズ・ディー・ディーＬｅｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｄ．Ｄ． ポリペプチドのα−アミド化および／またはＣ末端アミノ酸開裂を制御するための細胞培養用培地およびプロセス
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3110941A4 (en) * 2014-02-25 2017-10-18 Dr. Reddy's Laboratories Ltd. Process for modifying galactosylation and g0f content of a glycoprotein composition by glutamine supplementation
WO2015128314A1 (en) 2014-02-27 2015-09-03 F. Hoffmann-La Roche Ag Modulation of cell growth and glycosylation in recombinant glycoprotein production
WO2016089919A1 (en) 2014-12-01 2016-06-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
KR102007930B1 (ko) * 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
EP3042952A1 (en) * 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
EP3298036B1 (en) 2015-05-22 2022-04-06 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
WO2016196621A1 (en) 2015-06-01 2016-12-08 Biogen Ma Inc. Manganese supplementation for control of glycosylation in mammalian cell culture process
CN104894055B (zh) * 2015-06-15 2018-07-17 成都金凯生物技术有限公司 一种优化的细胞培养基、细胞培养方法及其在制备蛋白和抗体中的应用
KR101932137B1 (ko) * 2017-01-02 2018-12-24 연세대학교 산학협력단 당화 증강용 조성물 및 당화 증강된 단백질의 제조방법
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
HUP1800376A2 (hu) * 2018-11-07 2020-05-28 Richter Gedeon Nyrt Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
WO2022204120A1 (en) * 2021-03-23 2022-09-29 Biogen Ma Inc. Reducing host cell impurities during recombinant protein production

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NO162160C (no) 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
SU1587450A1 (ru) * 1988-05-04 1990-08-23 Институт биоорганической химии АН БССР Способ разделени гликозилированной и негликозилированной форм пролактина биологического материала
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5156964A (en) 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5118816A (en) 1990-12-26 1992-06-02 American Cyanamid Company 2-aryl-5-(trifluoromethyl)-2-pyrroline compounds useful in the manufacture of insecticidal, nematocidal and acaricidal arylpyrroles
CA2372251A1 (en) 1991-01-21 1992-08-06 Michael John Mullan Test and model for alzheimer's disease
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
AU729579B2 (en) 1996-10-23 2001-02-01 Trustees Of The University Of Pennsylvania, The Immunotherapy and improved vaccines
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
EP1047938A2 (en) 1998-01-12 2000-11-02 Betagene, Inc. Identification of substances that modify cellular secretory function
EP1078093B1 (en) 1998-02-27 2011-06-08 The Trustees of The University of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
ATE378066T1 (de) 1998-09-30 2007-11-15 Wyeth Corp Mutiertes cholera holotoxin als hilfsmittel
WO2000065070A2 (en) * 1999-04-26 2000-11-02 Genentech, Inc. Cell culture process for glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
IL151857A0 (en) 2000-03-22 2003-04-10 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
AU2002322380B2 (en) 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
DE60234695D1 (de) 2001-06-07 2010-01-21 Univ Colorado Mutantenformen von cholera holotoxin als adjuvans
PL224150B1 (pl) 2002-05-02 2016-11-30 Wyeth Corp Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
CA2492267C (en) 2002-07-15 2013-09-10 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
AR058140A1 (es) 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
EP1943333A2 (en) * 2005-11-02 2008-07-16 Wyeth a Corporation of the State of Delaware Methods for adapting mammalian cells
EP3026109B1 (en) * 2005-12-08 2022-03-09 Amgen Inc. Improved production of glycoproteins using manganese
EP3255141B1 (en) 2006-07-13 2021-12-01 Wyeth LLC Production of antibodies with improved glycosylation pattern

Also Published As

Publication number Publication date
EP2041270A1 (en) 2009-04-01
PT2041270E (pt) 2013-12-27
JP5401310B2 (ja) 2014-01-29
BRPI0714212B8 (pt) 2021-05-25
KR101495549B1 (ko) 2015-02-25
CA2657248A1 (en) 2008-01-17
PL2041270T3 (pl) 2014-04-30
HK1214307A1 (zh) 2016-07-22
DK2495307T3 (en) 2018-05-07
AU2007272957A1 (en) 2008-01-17
CA2657248C (en) 2018-10-30
US20080081356A1 (en) 2008-04-03
KR20090029841A (ko) 2009-03-23
EP3255141B1 (en) 2021-12-01
MX2009000349A (es) 2009-03-09
DK2041270T3 (da) 2014-01-27
PL2495307T3 (pl) 2018-07-31
EP2495307B1 (en) 2018-02-21
AR061976A1 (es) 2008-08-10
RU2463345C2 (ru) 2012-10-10
ES2440487T3 (es) 2014-01-29
BRPI0714212B1 (pt) 2021-01-19
WO2008008360A1 (en) 2008-01-17
JP2009543550A (ja) 2009-12-10
BRPI0714212A2 (pt) 2013-03-26
EP2041270B1 (en) 2013-11-20
US8129145B2 (en) 2012-03-06
DK3255141T3 (da) 2022-01-31
SI2495307T1 (en) 2018-05-31
CN104878064A (zh) 2015-09-02
HUE039128T2 (hu) 2018-12-28
IL196252A (en) 2016-02-29
PT2495307T (pt) 2018-05-10
EP3255141A1 (en) 2017-12-13
AU2007272957B2 (en) 2014-05-01
CN101541950A (zh) 2009-09-23
ES2668212T9 (es) 2018-05-30
EP2495307A1 (en) 2012-09-05
ES2668212T3 (es) 2018-05-17
TR201807021T4 (tr) 2018-06-21
EP2495307B9 (en) 2018-05-02
IL196252A0 (en) 2011-08-01
RU2008152449A (ru) 2010-08-20
DK2495307T5 (en) 2018-07-16
TW200812577A (en) 2008-03-16

Similar Documents

Publication Publication Date Title
PE20081194A1 (es) Produccion de glicoproteinas
AR110864A2 (es) Procesos para cultivos celulares
PE20090731A1 (es) Metodos de produccion de proteinas basados en medios de cultivos celulares que comprenden compuestos anti-senescencia
PE20100448A1 (es) PRODUCCION DE TNFR-Ig
AR004938A1 (es) Proteina derivada de alfa-hordotionina de alto contenido en metionina, secuencias de nucleotidos, arn y adn, cassete de expresion, vector detransformacion bacteriana, celulas bacterianas y vegetales transformadas, celula o cultivo de tejidos de maiz y metodo para potenciar el contenido de
ATE549395T1 (de) Medium und kultur von embryonalen stammzellen
BRPI0810343A2 (pt) dispositivo descartável para o cultivo e colheita de tecidos vegetais e/ou células, método de cultivo e colheita de um tecido vegetal e/ou células vegetais em um volume maior do que 400 litros e sistema de cultivo da célula vegetal
WO2002076285A3 (en) Composition and methods fro the production of biological tissues and tissue constructs
DK1404811T3 (da) Carbonmonoxid forbedrer resultater i vævs- og organtransplantationer og undertrykker apoptose
CY1108329T1 (el) Κυτταρικη καλλιεργεια
CN102147417B (zh) 苹果属植物生长素免疫组织定位的方法及其应用
ZA200800517B (en) Transplastomic plants expressing lumen-targeted protein
SG10201803982TA (en) Antibodies and processes for preparing the same
TW200636068A (en) A method of culturing a cell and use of the same
RU2006146795A (ru) Композиция для стимулирования роста и регенерации клеток, а также способы ее получения
ATE342275T1 (de) Vorübergehend-immortalisierte zellen zur verwendung in gentherapie
WO2008153366A3 (en) Method for manufacturing active recombinant blood coagulation factor ix
ES2657487T3 (es) Agentes de fijación exentos de formalina para tinciones histológicas de muestras de tejidos
BR112022014327A2 (pt) Método de cultivo de células humanas, composição de meio de cultura para cultivar células humanas e células humanas
DK1689461T5 (da) Anvendelse af en hydrogel til dyrkning af chondrocytter
WO2010138873A8 (en) Long term expansion of human hematopoietic stem cells
AR064703A1 (es) Lineas celulares inmortales diferenciadas capaces de producir albumina y factores de coagulacion , procedimientos para su preparacion a partir de una linea celular leucemica y sus empleos
WO2004113515A3 (en) Tissue modeling in embryonic stem (es) cell system
BRPI0518449A2 (pt) mÉtodos para produzir cÉlulas mamÍferas
BRPI0403200A (pt) Método para recrescimento de células embriogênicas crioconservadas de conìferas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal